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Purpose
This study focused on implementation of a prognostic scoring index based on clinico-labo-
ratory parameters measured routinely on admission in metastatic pancreatic cancer 
patients. 
Materials and Methods
Records from 403 patients of metastatic disease were analyzed retrospectively. Continuous
variables were dichotomized according to the normal range or the best cut-off values sta-
tistically determined by Contal and O’Quigley method, and then analyzed in association with
prognosis—overall survival (OS), using Cox’s proportional hazard model. Scores were calcu-
lated by summing the rounded chi-square scores for the factors that emerged in the multi-
variate analysis. 
Results
Performance status, hemoglobin, leucocyte count, neutrophil-lymphocyte ratio, and carci-
noembryonic antigen were independent factors for OS. When patients were divided into
three risk groups according to these factors, median survival was 11.7, 6.2, and 1.3 months
for the low, intermediate, and high-risk groups, respectively (p < 0.001). Palliative
chemotherapy has a significant survival benefit for low and intermediate-risk patients 
(median OS; 12.5 months vs. 5.9 months, p < 0.001 and 8.0 months vs. 2.0 months, 
p < 0.001, respectively). 
Conclusion
We advocate the use of a multivariable approach with continuous variables for prognostic
modeling. Our index is helpful in accurate patient risk stratification and may aid in treatment
selection. 
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Introduction
Pancreatic ductal adenocarcinoma (PDAC) is the fourth
most common cause of cancer-related mortality in the West-
ern world. Only 5%-20% of patients are candidates for cura-
tive pancreatectomy and most cases of PDAC are diagnosed
at advanced stages, leading to dismal prognosis [1]. Numer-
ous chemotherapy drugs have been investigated alone and
in combination for the treatment of advanced PDAC but
have shown little or no impact on disease progression or sur-
vival. In the two recent clinical trials, FOLFIRINOX (5-fluo-
rouracil, leucovorin, irinotecan, and oxaliplatin) and gem-
citabine plus nanoparticle albumin-bound paclitaxel showed
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superior outcomes compared with gemcitabine alone [1].
However, these new regimens are associated with consider-
able toxicities and the long-term survival remains unsatisfac-
tory. 
Identification of prognostic factors is crucial in guiding
personalized medicine. Such factors help patients to avoid
unnecessary toxicity and complications from aggressive
treatment and can further facilitate stratification for clinical
trials. Many studies have examined various preoperative/
postoperative factors predictive of treatment outcomes [2].
However, their significance is still questionable, as most have
been identified based on small sample sizes with inadequate
statistical power. Widely suggested parameters are derived
from functional and nutritional status, distant metastasis,
and laboratory findings including C-reactive protein (CRP),
carcinoembryonic antigen (CEA), and carbohydrate antigen
19-9 (CA 19-9) [3]. However, the role of these parameters is
not affirmed, and the risk of bias subsists when the choice of
cutoff for the continuous variables is random, leading to the
use of different cutoff points across multiple studies, which
impedes direct comparison. In addition, regarding advanced
disease which is unresectable or metastatic, few risk scoring
indices were available, and the majority focused on predic-
tion after chemotherapy—particularly gemcitabine [4]. How-
ever, it is more important in the clinical field to discriminate
patients who might benefit from chemotherapy from those
who cannot. Therefore, the aim of this study is to determine
prognostic values of clinic-laboratory parameters routinely
evaluated at the time of diagnosis, leading to implementation
of a scoring index for use in effective identification of differ-
ent risk patient groups.
Materials and Methods
1. Patients
From July 2006 to April 2014, 482 patients were diagnosed
with pancreatic cancer at Gangnam Severance Hospital,
Seoul, Korea. Diagnosis was made from surgical excision, tis-
sue biopsy, or cytology. Inclusion criteria for further analysis
were as follows: (1) age > 18 years, (2) histologically con-
firmed diagnosis of PDAC, (3) metastatic disease at the time
of diagnosis or systemic recurrence after curative resection,
and (4) available electronic medical records (including treat-
ment information). 
Exclusion criteria were as follows: (1) brain or leptom-
eningeal metastasis; (2) locally advanced disease who recei-
ved definitive chemoradiotherapy; and (3) other histology
types such as cystic neoplasms, neuroendocrine tumors, or
lymphomas; or (4) synchronous advanced malignancies. A
total of 403 patients fulfilled the inclusion criteria and were
analyzed retrospectively. The institutional review board 
approved this retrospective study and the requirement to 
obtain informed consent was waived. 
2. Data collection
The following baseline data were recorded at the time of
diagnosis: age, sex, previous pancreatectomy, tumor loca-
tion, Eastern Cooperative Oncology Group (ECOG) perform-
ance status (PS), metastatic site(s), presence of diabetes
mellitus, presence of thromboembolism, and body mass
index (BMI). Hematological and blood chemistry values 
included hemoglobin, white blood cell (WBC) count, serum
protein, albumin, total bilirubin, cholesterol, blood urea 
nitrogen (BUN), alkaline phosphatase (ALP), aspartate
aminotransferase (AST), alanine aminotransferase (ALT),
CRP, CEA, and CA 19-9. Neutrophil-to-lymphocyte ratio
(NLR) was calculated by dividing absolute neutrophil count
by absolute lymphocyte count. 
Computed tomography (CT) of chest and abdomino-
pelvis, radionuclide bone scan, and 18F-fluorodeoxyglucose
positron emission tomography were performed for evalua-
tion of distant metastasis. Radiological detection of peri-
toneal carcinomatosis relied on the following findings
evaluated by independent radiologist(s): thickening and
nodular enhancement of peritoneal reflections, multiple soft
tissue nodules, stranding and thickening of the omentum
(omental cake), stranding and distortion of the small bowel
mesentery, and ascites, especially if loculated. The presence
of ascites was inferred from evidence of paracentesis and 
malignant cell detection in cytology examination, or from
suspicious fluid collection on CT or ultrasonogram. 
3. Statistical analysis
Hematological and blood chemistry values were initially
recorded as continuous variables and later transformed into
categorical variables according to the upper normal values
(hemoglobin, WBC, serum protein, albumin, bilirubin, BUN,
ALP, AST, and ALT) [5] or the best cutoff point (NLR, CRP,
CEA, and CA 19-9) determined using the Contal and
O’Quigley method, which calculates the maximizing hazard
ratio (HR) based on log rank statistics and estimates the best
cut-off value [6]. 
Overall survival (OS) was defined as the time from the
date of diagnosis until death from any cause. Survival curves
were generated using the Kaplan-Meier method and com-
pared using the log-rank test. Univariate analysis was per-
formed to determine the association of the following
prognostic factors with OS: age, sex, previous pancreatec-
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tomy, tumor location, PS, diabetes mellitus, liver metastasis,
peritoneal carcinomatosis, thromboembolism, BMI, hemo-
globin, WBC count, NLR, serum protein, albumin, bilirubin,
BUN, ALP, AST, ALT, CRP, CEA, and CA 19-9. A stepwise
multivariate analysis with Cox’s proportional hazard model
was performed using significant factors in the univariate
analysis. HRs, 95% confidence intervals (CIs), and chi-sqaure
scores were obtained for all regressions. 
A risk scoring system was devised by summing the
rounded chi-sqaure scores of the independent prognostic fac-
tors identified in the multivariate analysis. Finally, patients
were grouped according to the best cutoff value as calculated
by K-adaptive partitioning, which calculates the best cutoff
value by selection of maximizing the sum of pairwise log-
rank statistics [7]. Discriminatory power of the scoring sys-
tem was assessed using Harrell’s c-index [8]. A p-value of 
< 0.05 was considered statistically significant. 
Statistical analyses were performed using PASW Statistics
ver. 18.0 (SPSS Inc., Chicago, IL), SAS ver. 9.2 (SAS Institute
Inc., Cary, NC), and R ver. 3.1.3 (kaps Add-on Package; 
Institute for Statistics and Mathematics, Vienna, Austria;
http://www.R-project.org).
Results
The median follow-up period was 7.9 months (range, 0.1
to 70.5 months) from diagnosis. Baseline patient characteris-
tics are shown in Table 1. The median age was 66 years, and
198 patients (49.1%) were men. Sixty-two patients (15.4%)
underwent curative resection, 217 patients (53.8%) had an
ECOG PS of 0-1, and 178 (44.2%) and 79 (19.6%) patients had
liver metastasis and peritoneal carcinomatosis at the time of
diagnosis, respectively. The median value of NLR was 2.92,
and the median value of CEA and CA 19-9 was 4.4 ng/mL
and 224.5 U/mL, respectively.  
1. Survival analysis
Median OS for total patients was 8.2 months (95% CI, 
7.3 to 9.1). The statistically determined best cutoff points
were as follows: 3.0 for NLR, 6.0 mg/L for CRP, 7.0 ng/mL
for CEA, and 453.0 U/mL for CA 19-9. Significantly extended
survival was observed in patients with low NLR levels com-
pared with high NLR (median OS, 11.3 months vs. 4.7 mont-
hs; p < 0.001) (Fig. 1A). Patients with low levels of CRP, CEA,
or CA 19-9, respectively, also showed superior survival 
(median OS; CRP: 11.3 months vs. 5.0 months, p < 0.001; CEA:
10.9 months vs. 5.7 months, p < 0.001; CA 19-9: 10.3 months vs.
6.5 months, p < 0.001) (Fig. 1B-D). 
Table 1. Patient characteristics 
Characteristic No. (%)
Age, median (range, yr) 66 (29-96)
Sex
Male 198 (49.1)
Female 205 (50.9)
Previous pancreatectomy
Yes 62 (15.4)
No 341 (84.6)
Tumor location
Head 226 (56.1)
Body/Tail 177 (43.9)
ECOG performance status
0-1 217 (53.8)
2 127 (31.5)
3-4 59 (14.6)
Diabetes mellitus
No 260 (64.5)
Yes 143 (35.5)
Liver metastasis
No 225 (55.8)
Yes 178 (44.2)
Peritoneal carcinomatosis
No 324 (80.4)
Yes 79 (19.6)
Thromboembolism
No 370 (91.8)
Yes 33 (8.2)
BMI, median (range, kg/m2) 22.05 (13.1-35.6)
Hematologic values, median (range)
Hemoglobin (g/dL) 12.3 (4.6-18.3)
WBC count (/µL) 6,560 (2,280-23,430)
NLR 2.92 (0.52-34.52)
Blood chemistry values, median (range)
Protein (g/dL) 6.75 (4.4-8.8)
Albumin (g/dL) 4.2 (2.1-5.7)
Bilirubin (mg/dL) 0.7 (0.1-30)
BUN (mg/dL) 13.5 (4.2-116.2)
ALP (IU/L) 101 (30-1,478)
AST (IU/L) 27 (10-666)
ALT (IU/L) 25 (5-552)
CRP (mg/L) 6.3 (0.1-314.4)
CEA (ng/mL) 4.4 (0.3-8,168.6)
CA 19-9 (U/mL) 224.55 (0.5-20,850)
Palliative treatment
Gemcitabine monotherapy 87 (21.6)
Gemcitabine doublet therapy 163 (40.4)
Fluoropyrimidine-based therapy 36 (8.9)
RTx with chemotherapy 29 (7.2)
No treatment 88 (21.8)
ECOG, Eastern Cooperative Oncology Group; BMI, body
mass index; WBC, white blood cell; NLR, neutrophil-lym-
phocyte ratio; BUN, blood urea nitrogen; ALP, alkaline
phosphatase; AST, aspartate aminotransferase; ALT, ala-
nine aminotransferase; CRP, C-reactive protein; CEA, car-
cinoembryonic antigen; CA 19-9, carbohydrate antigen
19-9; RTx, radiotherapy.
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In univariate analysis, age, previous pancreatectomy,
tumor location, PS, liver metastasis, peritoneal carcinomato-
sis, BMI, hemoglobin, WBC count, NLR, serum albumin,
BUN, ALP, AST, CRP, CEA, and CA 19-9 showed significant
association with OS (Table 2). In multivariate analysis, ECOG
PS, hemoglobin, WBC count, NLR, and CEA were significant
in both forward and backward stepwise analyses (Table 3). 
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Fig. 1. Kaplan-Meier curves of overall survival for all patients (n=403) according to neutrophil-to-lymphocyte ratio (NLR)
(A), C-reactive protein (CRP) (B), carcinoembryonic antigen (CEA) (C), and carbohydrate antigen 19-9 (CA 19-9) (D).
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Table 2. Univariate analysis for overall survival
Factor No. HR (95% CI) p-value
Age (yr)
< 66 198 1 ( 0.007
 66 205 1.334 (1.081-1.646)
Sex
Male 198 1 ( 0.054
Female 205 1.228 (0.996-1.514)
Previous pancreatectomy 
Yes 62 1 ( 0.016
No 341 1.454 (1.073-1.972)
Tumor location
Head 226 1 ( 0.004
Body/Tail 177 1.369 (1.108-1.691)
ECOG performance status
0-1 217 1 ( < 0.001
2 127 1.728 (1.366-2.185)
3-4 59 4.991 (3.673-6.782)
Diabetes mellitus
No 260 1 ( 0.941
Yes 143 1.008 (0.811-1.254)
Liver metastasis
No 225 1 ( < 0.001
Yes 178 1.46 (1.182-1.805)
Peritoneal carcinomatosis
No 324 1 ( < 0.001
Yes 79 2.09 (1.618-2.7)
Thromboembolism
No 370 1 ( 0.099
Yes 33 1.36 (0.944-1.959)
BMI (kg/m2)
 18.5 342 1 ( 0.006
< 18.5 54 1.52 (1.125-2.054)
Hemoglobin (g/dL)
Normal ( 12) 237 1 ( < 0.001
Abnormal (< 12) 166 1.601 (1.292-1.983)
WBC count (103/µL)
Normal (< 10.8) 356 1 ( < 0.001
Abnormal ( 10.8) 47 2.936 (2.15-4.009)
NLR
< 3 209 1 ( < 0.001
 3 194 2.254 (1.823-2.788)
Protein (g/dL)
Normal ( 6.9) 172 1 ( 0.884
Abnormal (< 6.9) 230 1.016 (0.822-1.256)
Albumin (g/dL)
Normal ( 3.4) 353 1 ( < 0.001
Abnormal (< 3.4) 50 2.1 (1.542-2.86)
Bilirubin (mg/dL)
Normal (< 1.2) 285 1 0.852
Abnormal ( 1.2) 118 0.978 (0.778-1.231)
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Table 2. Continued
Factor No. HR (95% CI) p-value
BUN (mg/dL)
Normal (< 23.0) 363 1 ( 0.006
Abnormal ( 23.0) 39 1.638 (1.153-2.327)
ALP (IU/L)
Normal (< 123) 226 1 ( < 0.001
Abnormal ( 123) 172 1.579 (1.276-1.952)
AST (IU/L)
Normal (< 30) 219 1 ( 0.006
Abnormal ( 30) 183 1.34 (1.086-1.653)
ALT (IU/L)
Normal (< 33) 237 1 ( 0.893
Abnormal ( 33) 165 0.986 (0.796-1.219)
CRP (mg/L)
< 6 180 1 ( < 0.001
 6 193 1.88 (1.512-2.336)
CEA (ng/mL)
< 7 242 1 ( < 0.001
 7 161 2.332 (1.866-2.915)
CA 19-9 (U/mL)
< 453 229 1 ( < 0.001
 453 169 1.927 (1.545-2.405)
HR, hazard ratio; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; BMI, body mass index; WBC, white
blood cell; NLR, neutrophil-lymphocyte ratio; BUN, blood urea nitrogen; ALP, alkaline phosphatase; AST, aspartate amino-
transferase; ALT, alanine aminotransferase; CRP, C-reactive protein; CEA, carcinoembryonic antigen; CA 19-9, carbohydrate
antigen 19-9.
Table 3. Multivariate analysis for overall survival
Factor  score HR (95% CI) p-value
ECOG performance status
0-1 1 ( < 0.001
2 11.2 1.53 (1.19-1.96)
3-4 54.2 3.60 (2.56-5.06) 
Hemoglobin (g/dL)
 12 1 ( 0.008
< 12 7.0 1.36 (1.08-1.70) 
WBC count (103/µL)
< 10.8 1 ( 0.002
 10.8 9.6 1.77 (1.23-2.55)
NLR
< 3 1 ( < 0.001
 3 21.0 1.78 (1.39-2.28)
CEA (ng/mL)
< 7 1 ( < 0.001
 7 50.9 2.43 (1.90-3.10) 
HR, hazard ratio; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; WBC, white blood cell; NLR, neu-
trophil-lymphocyte ratio; CEA, carcinoembryonic antigen.
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2. Prognosis scoring system
A prognostic system was devised using these five inde-
pendent prognostic factors. Scores were calculated by sum-
ming the rounded chi-squre scores of these factors (Table 4):
2 (ECOG PS=2) or 11 (ECOG PS  3)+1 (hemoglobin < 12 g/
dL)+2 (WBC count  10,800/µL)+4 (NLR  3.0)+10 (CEA  
7 ng/mL). The scores ranged from 0 to 28, and the maximally
discriminative cut-off values were 6 and 25, respectively.
Patients were then categorized according to three sub-
groups based on their scores: low (198 [49.1%]), intermediate
(182 [45.2%]), and high-risk groups (23 [5.7%]). The median
OS was 11.7 months (95% CI, 10.2 to 13.2), 6.2 months (95%
CI, 5.0 to 7.4), and 1.3 months (95% CI, 0.9 to 1.7), respectively
(p < 0.001) (Fig. 2). One-year survival rate was 49.0%, 18.9%,
and 0%, respectively. The internally validated Harrell’s 
c-index of the scoring system was 0.731 (95% CI, 0.696 to
0.766).
3. Association with treatment outcome
Of the 403 patients, 315 (78.2%) underwent palliative
chemotherapy and 88 (21.8%) refused chemotherapy, receiv-
ing supportive care only. Palliative chemotherapy included
gemcitabine monotherapy (21.6%), gemcitabine doublet
(40.4%), and fluoropyrimidine-based chemotherapy (8.9%).
Radiotherapy was performed with palliative aim in 7.2% of
patients. With these different kinds of chemotherapy regi-
mens, there were no significant differences in OS. 
Patients receiving chemotherapy had significantly longer
survival than patients who received best supportive care
only (median OS, 10.3 vs. 2.5 months; p < 0.001). One hun-
dred seventy-five (88.4%), 138 (75.8%), and only two patients
(8.7%) in the low, intermediate, and high-risk groups 
received chemotherapy, respectively. Palliative chemother-
apy provided patients with a survival benefit in the low-risk
group (median OS, 12.5 months vs. 5.9 months; p < 0.001)
(Fig. 3A), and patients in the intermediate-risk group also
benefitted from chemotherapy (median OS, 8.0 vs. 2.0
months; p < 0.001) (Fig. 3B). However, no survival difference
was observed with chemotherapy in the high-risk group
(median OS, 3.7 vs. 1.2 months; p=0.163) (Fig. 3C). 
Discussion
Pancreatic cancer is the only human malignancy for which
patients' survival has rarely improved during the past 30
years. Chemotherapy remains the mainstay of treatment in
metastatic pancreatic cancer. However, current systemic
Table 4. Components of the prognostic prediction score
for pancreatic ductal adenocarcinoma
Factor Score
ECOG performance status
0-1 0
2 +2
3-4 +11
Hemoglobin (g/dL)
 12 0
< 12 +1
WBC count (103/µL)
< 10.8 0
 10.8 +2
NLR
< 3 0
 3 +4
CEA (ng/mL)
< 7 0
 7 +10
ECOG, Eastern Cooperative Oncology Group; WBC,
white blood cell; NLR, neutrophil-lymphocyte ratio; CEA,
carcinoembryonic antigen. 
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Fig. 2.  Kaplan-Meier overall survival curves according to
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groups based on prognostic prediction score: low risk, 
0-6; intermediate risk, 7-25; and high risk, 26-28.
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treatments offer only a modest benefit in tumor-related
symptoms and survival and these benefits, if any, are usually
limited to patients—even with a novel regimen of FOLFIRI-
NOX—with good PS and adequate nutritional status, and
abrupt changes in clinical status may occur in debilitated 
patients with advanced disease despite systemic treatment.
Therefore, primary point was (1) how to predict survival of
patients at the time of initial diagnosis and (2) how to differ-
entiate patients who might benefit from chemotherapy from
those cannot. 
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Fig. 3. Kaplan-Meier overall survival survival curves according to palliative treatment in the low-risk (A), intermediate-risk
(B), and high-risk (C) groups.
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In general, pancreatic cancer patients are not clinically sep-
arated into prognostic groups, with the exception of surgical
status, before treatment. Therefore, limited studies have 
focused on metastatic disease [3,4]. A previous Korean study
reported liver metastasis, peritoneal seeding, high CRP, and
low serum albumin as poor indicators of OS. A western
study reported age, weight loss, and metastasis as poor prog-
nostic factors. Both studies focused on gemcitabine-treated
patients, and are small retrospective analyses with question-
able statistical powers. However, pancreatic cancer is a het-
erogeneous disease and recent introduction of the three-drug
combination regimen or the new taxane represent key 
advances for better control of the disease over gemcitabine,
which requires a new prognostic model. 
Another debate was cutoff points of routinely measured
tumor markers—CRP, CEA, and CA 19-9 [9]. Using a chemi-
luminescence immunoassay, the standard diagnostic cutoff
points for CA 19-9 and CEA were 37 IU/mL and 5 ng/mL,
respectively [10]. However, the cut-off points for these vari-
ables have not been established in metastatic disease. Some
researchers advocate that CA 19-9 serum level of < 100
U/mL implies likely resectable disease, while levels > 100
U/mL may suggest unresectablity or metastatic disease [11].
However, most studies used median values or normal ranges
for dichotomization. For dichotomizing continuous vari-
ables, splits of some percentile or average are arbitrary and
may not be useful in assessing the true prognostic value of
variables [12]. In our study, instead, cutoff point was derived
using the Contal and O’Quigley method, which selects the
cut-off point that maximizes the model likelihood only after
all possible cut-offs have been evaluated [6]. In addition, 
K-adaptive partitioning for the survival model was used to
determine minimum p-value.
The purpose of implementing a scoring system is for clin-
ical decision-making and patient risk stratification, using
routinely measurable clinical parameters on admission. In
this study PS, hemoglobin, WBC, NLR, and CEA were iden-
tified as independent prognostic markers. For patients with
a score of  6, we may hypothesize that their survival can be
extended up to 12.5 months by chemotherapy, which pro-
vides us with a rationale for recommendation of relatively
aggressive treatment such as FOLFIRINOX. Conversely,
high-risk group (score > 25) patients had an extremely poor
prognosis, with a median survival duration of only 1.3
months and the 1-year survival rate was less than 1%.
Chemotherapy has no statistical benefit in these patients, but
it is impetuous for now to declare that chemotherapy is con-
traindicated for the high risk group, in which only two 
patients who received chemotherapy were included for
analysis. Intermediate-risk patients showed comparable out-
comes with gemcitabine-based treatment. Thus, we can rec-
ommend conventional gemcitabine-based therapy to these
patients. Ultimately, these findings suggest that this scoring
system can be helpful in selection of the "right" patients for
the "right" treatment.
Several previous studies reported reduced survival in 
patients with elevated CA 19-9 levels [13]. However, CA 
19-9 was not included in our system. We believe increased
false positive results in the presence of obstructive jaundice
and inflammation—20% of our patients accompanied 
obstructive jaundice and 12% with systemic leucocytosis—
could severely limit the universal applicability of serum CA
19-9 levels in pancreatic cancer management. Instead, our
study showed that NLR, leukocytosis, and CEA were inde-
pendent. Hypothesis of the role of inflammation in develop-
ment and prognosis of cancer has been examined and several
studies have suggested that NLR and WBC count are indica-
tive of survival [3,14]. Whether the systemic inflammation is
malignancy-associated or is the result of any co-morbid con-
ditions that cancer patients may suffer is still unclear, but
here we assumed that systemic inflammation might also
occur in commonly prevalent conditions. One plausible 
explanation is that cellular response of blood components
might be mediated through endothelial dysfunction, leading
to depletion of vasodilator, antithrombotic, and anti-athero-
genic properties of the endothelium and may result in capil-
lary leukocytosis and subsequent increased vascular
resistance [15]. In addition, high neutrophil counts reflect 
inflammation, whereas low lymphocyte counts reflect mal-
nutrition [16]. Cytokine-mediated systemic inflammation has
been shown to promote angiogenesis, DNA damage resp-
onse, and tumor invasion [17]. NLR has recently been repo-
rted as a prognostic marker in colorectal and lung cancers
[14,15], and its prognostic value in pancreatic cancer has also
been reported [18]. Although an NLR cut-off value of 4.0 or
5.0 has been shown to have significant prognostic value in
resectable cancers, a cutoff point of 3.0 may be reasonable for
survival predication, which is consistent with a previous 
report [18-20].  
The significance of CEA in pancreatic cancer has been
rarely investigated [3]. CEA functions as an adhesion mole-
cule during metastasis, and Hostetter et al. [21] reported that
CEA increases the percentage of colorectal liver metastases
from 2% to 48% in vivo. In a small study, CEA was identified
as prognostic in advanced pancreatic cancer; superior sur-
vival outcome has been reported in patients with low CEA
levels (< 2.5 ng/mL) compared to those with high CEA levels
[22]. Although the cut-off value for CEA in our study was 7
ng/mL, further evaluation is warranted to elucidate the role
of CEA in pancreatic cancer. Another factor, hemoglobin
level, has been reported as a poor prognostic factor and is 
reflective of nutrition or general condition [23]. 
However, a prognostic model using clinical parameters
only had a limitation in that tumor biology could not be 
VOLUME 48  NUMBER 4  OCTOBER  2016 1261
Cancer Res Treat. 2016;48(4):1253-1263
reflected. In pancreatic cancer, K-ras mutations occur in 90%
of cases, and overexpression of growth factors such as epi-
dermal growth factor, transforming growth factor  is com-
mon [24]. In addition, expression of these growth factors and
their receptor has been found to show association with 
decreased survival, thus, a combined approach using both
clinical parameters and biologic markers is warranted for 
implementation of a more robust prognostic model. How-
ever, our system showed a Harrell’s c-index of 0.731, indi-
cating sufficient discrimination power for patients according
to the risk, and it warrants prospective clinical utility [25].
Another limitation of this study is the retrospective and non-
randomized design. Patients underwent heterogeneous
treatments including gemicitabine monotherapy or doublet,
fluoropyrimidines, oral chemotherapy or even concurrent
chemoradiotherapy which might have affected differential
influence on survival.
Conclusion
In conclusion, we found that NLR and CEA were inde-
pendent prognostic factors and suggest 3.0 for NLR and 
7 ng/mL for CEA as statistically determinant cut-off values
for prognostic dichotomization. In addition, our prognostic
scoring system provides rationale for risk stratification of 
advanced PDAC patients, leading to individualized treat-
ment. Further studies are needed to evaluate the accuracy of
this scoring system.
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